Figure 2From: Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line modelSensitivity of gefitinib, erlotinib, ZSTK474 and sirolimus alone and in combination on the parental MCF10a breast cancer cell line compared with isogenic clones with EGFR, KRAS and PI3K mutations. A sensitivity index of zero = complete inhibition, 600 = no inhibition.Back to article page